Advertisement
UK markets close in 5 hours 2 minutes

  • FTSE 100

    8,059.02
    +35.15 (+0.44%)
     

  • FTSE 250

    19,712.16
    +112.77 (+0.58%)
     

  • AIM

    752.81
    +3.63 (+0.48%)
     

  • GBP/EUR

    1.1591
    +0.0002 (+0.02%)
     

  • GBP/USD

    1.2358
    +0.0008 (+0.06%)
     

  • Bitcoin GBP

    53,583.43
    +113.70 (+0.21%)
     

  • CMC Crypto 200

    1,421.92
    +7.16 (+0.51%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    81.90
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,313.30
    -33.10 (-1.41%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,021.62
    +160.82 (+0.90%)
     

  • CAC 40

    8,078.96
    +38.60 (+0.48%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

FDA panel votes in favor of approval of Glaxo lung drug Anoro

Reuters - UK Focus

WASHINGTON, Sept 10 (Reuters) - An federal advisory panel has recommended that the U.S. Food and Drug Administration approve a drug made by GlaxoSmithKline Plc (Other OTC: GLAXF - news) and Theravance Inc (NasdaqGS: THRX - news) to treat chronic obstructive pulmonary disease.

The panel voted 11-2 to approve the drug, Anoro, an inhaled combination of vilanterol, a long-acting beta-agonist that is designed to open the airways, and umeclidinium, a long-acting muscarinic receptor antagonist, which works to improve lung function.

The FDA is not required to follow the advice of its advisory panels but typically does so.

Analysts expect the drug to generate sales of more than $2 billion a year by 2018 according to the average estimate of six analysts polled by Thomson Reuters.

A decision is expected by Dec. 18. (Reporting by Toni Clarke in Washington; Editing by Carol Bishopric)